CGP52411

CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease[1][2].

Product Specifications

CAS Number

145915-58-8

Product Name Alternative

DAPH

UNSPSC

12352005

Hazard Statement

H302

Target

Amyloid-β; EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cgp52411.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NC(C2=C1C=C(NC3=CC=CC=C3)C(NC4=CC=CC=C4)=C2)=O

Molecular Formula

C20H15N3O2

Molecular Weight

329.35

Precautions

H302

References & Citations

[1]Buchdunger E, et al. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci U S A. 1994 Mar 15;91 (6) :2334-8.|[2]Blanchard BJ, et al. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A. 2004 Oct 5;101 (40) :14326-32.